Trucheck and Functional Markers For Early Cancer Detection
Cancer is often called a ‘silent disease’ for good reason. Many of the most common cancers including breast, prostate, bowel, and lung, develop quietly, with few or no symptoms until they’re advanced. By the time they’re picked up by conventional screening or diagnostic scans, treatment options may be limited.
That’s why early cancer detection matters so much. While regular screening tests like mammograms, Pap smears, PSA tests, and colonoscopies play an essential role in cancer prevention, they don’t catch everything.
Dr Konrad Grosser offers advanced, integrative screening options that go beyond the standard approach. Using cutting-edge technologies like the Trucheck™ intelli multi-cancer screening test and detailed metabolic panels, Dr Grosser helps patients with early cancer detection – giving patients the best possible chance to treat the cancer early.
What conventional cancer screenings can miss
Most people are familiar with standard cancer screening tools. Women are offered mammograms to screen for breast cancer and cervical smears for cervical cancer. Men over 50 are often offered PSA blood tests to check for prostate issues. Bowel cancer screening via stool tests or colonoscopy is available in many regions, and lung cancer screening is sometimes offered for high-risk patients (such as long-term smokers).
These tests are vital, but they have limits. Many cancers including pancreatic, ovarian, kidney, and some blood cancers, currently have no routine screening. This is where Trucheck proves invaluable. It scans for circulating tumour markers in the blood and captures a much broader picture.
Trucheck: A multi-cancer blood test
The Trucheck test is a next-generation blood test that detects rare circulating tumour cells (CTCs) and their molecular signatures in the bloodstream. Unlike conventional tests that typically focus on a specific organ or cancer type, Trucheck™ intelli distinguishes up to 70 types of solid tumours that account for 81% of all cancer cases.
What makes this technology particularly exciting is its use of DNA and RNA analysis to detect abnormal cells long before symptoms arise. Research shows that certain cancers can shed detectable tumour cells into the bloodstream early in their development, offering a crucial window for early intervention.
Dr Grosser integrates Trucheck testing into his personalised screening plans, helping patients gain deeper insight into their cancer risk profile. It’s important to note: Trucheck is not a replacement for standard cancer screening. It does not detect all types of cancers and should be considered as a supplementary tool alongside the recommended screening tests.
Further diagnostic evaluations
Chronic inflammation and impaired immune surveillance can create a permissive environment for cancer to grow unchecked. Functional markers and metabolic panels assess the body’s inflammatory status, oxidative stress levels, and metabolic balance.
Elevated markers of oxidative stress can signal cellular damage, while imbalances in glucose or insulin regulation can increase the risk of certain cancers (such as breast and colon cancer).
By assessing your metabolic health alongside your Trucheck results, Dr Konrad Grosser takes a comprehensive, systems biology approach to explore any underlying issues. This may include advanced diagnostic testing and evaluation of related systems such as the gut microbiome and digestion, acid-base balance, hormonal function, and immune regulation, to fully understand how each contributes to your overall risk profile.
Once key issues are identified, Dr Grosser will work with you to develop a tailored plan that will include guidance on targeted nutrition, physical activity, and mental wellbeing, giving you a clear, proactive path toward long-term health.
If you want to take a proactive, personalised approach to cancer screening, get in touch to book your consultation with Dr Konrad Grosser.
